...
首页> 外文期刊>Hypertension: An Official Journal of the American Heart Association >Reassessment of Ambulatory Blood Pressure Improves Renal Risk Stratification in Nondialysis Chronic Kidney Disease Long-Term Cohort Study
【24h】

Reassessment of Ambulatory Blood Pressure Improves Renal Risk Stratification in Nondialysis Chronic Kidney Disease Long-Term Cohort Study

机译:在非透析慢性肾脏病长期队列研究中,对动态血压的重新评估可改善肾脏风险分层

获取原文
获取原文并翻译 | 示例
           

摘要

In nondialysis chronic kidney disease, ambulatory blood pressure (ABP) performs better than clinic BP in predicting outcome, but whether repeated assessment of ABP further refines prognosis remains ill-defined. We recruited 182 consecutive hypertensive patients with nondialysis chronic kidney disease who underwent 2 ABPs 12 months apart to evaluate the enhancement in risk stratification provided by a second ABP obtained 1 year after baseline on the risk (hazard ratio and 95% confidence interval) of composite renal end point (death, chronic dialysis, and estimated glomerular filtration rate decline 40%). The difference in daytime and nighttime systolic BP between the 2 ABPs (daytime and nighttime bias) was added to a survival model including baseline ABP. Net reclassification improvement was also calculated. Age was 65.6 +/- 13.4 years; 36% had diabetes mellitus and 36% had previous cardiovascular event; estimated glomerular filtration rate was 42.2 +/- 19.6 mL/min per 1.73 m(2), and clinic BP was 145 +/- 18/80 +/- 11 mm Hg. Baseline ABP (daytime, 131 +/- 16/75 +/- 10 and nighttime, 122 +/- 18/66 +/- 10 mm Hg) and daytimeighttime BP goals (58.2% and 43.4%) did not change at month 12. Besides baseline ABP values, bias for daytime and nighttime systolic BP linearly associated with renal outcome (1.12, 1.04-1.21 and 1.18, 1.08-1.29 for every 5-mm Hg increase, respectively). Classification of patients at risk improved when considering nighttime systolic level at second ABP (net reclassification improvement, 0.224; 95% confidence interval, 0.005-0.435). Patients with first and second ABPs above target showed greater renal risk (2.15, 1.29-3.59 and 1.71, 1.07-2.72, for daytime and nighttime, respectively). In nondialysis chronic kidney disease, reassessment of ABP at 1 year further refines renal prognosis; such reassessment should specifically be considered in patients with uncontrolled BP at baseline.
机译:在非透析慢性肾脏疾病中,动态血压(ABP)在预测结局方面比临床BP更好,但是对ABP的反复评估是否可以进一步改善预后仍然不确定。我们招募了182名连续的非透析性慢性肾脏病高血压患者,他们每12个月进行两次ABP,以评估基线后1年获得的第二次ABP对复合肾的风险(危险比和95%置信区间)提供的风险分层的增强终点(死亡,慢性透析和估计的肾小球滤过率下降40%)。 2个ABP之间的白天和夜间收缩压差异(白天和夜间偏差)被添加到包括基线ABP的生存模型中。还计算了净重分类改进。年龄为65.6 +/- 13.4岁; 36%的人患有糖尿病,36%的人以前有心血管事件;估计的肾小球滤过率是每1.73 m(2)42.2 +/- 19.6 mL / min,并且临床BP是145 +/- 18/80 +/- 11 mm Hg。基线ABP(白天131 +/- 16/75 +/- 10和夜间,122 +/- 18/66 +/- 10毫米汞柱)和白天/夜间BP目标(58.2%和43.4%)在第12个月。除基线ABP值外,白天和夜间收缩压的偏差与肾预后线性相关(每增加5 mm Hg分别为1.12、1.04-1.21和1.18、1.08-1.29)。考虑第二次ABP夜间收缩水平时,有风险的患者的分类得到改善(净重分类改善0.224; 95%置信区间0.005-0.435)。第一次和第二次ABP高于目标的患者显示出更高的肾脏风险(白天和晚上分别为2.15、1.29-3.59和1.71、1.07-2.72)。在非透析慢性肾脏疾病中,在1年时对ABP进行重新评估可进一步改善肾脏预后。基线血压不受控制的患者应特别考虑进行这种重新评估。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号